Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

6.130 -0.195 (-3.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
Coya Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Coya Therapeutics Announces $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
From Coya Therapeutics, Inc.
Via Business Wire
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at Upcoming Healthcare Conferences
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
From Coya Therapeutics, Inc.
Via Business Wire
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,... 
Via Benzinga
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.